Showing 1821-1830 of 3038 results for "".
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Outlook Therapeutics Completes Patient Dosing in Phase 3 NORSE TWO Trial for Wet AMDhttps://modernod.com/news/outlook-therapeutics-completes-patient-dosing-in-phase-3-norse-two-trial-for-wet-amd/2479279/Outlook Therapeutics reported that it has administered the final dose to the last patient enrolled in its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). Topline data are expected to be reported for NO
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant